You have 9 free searches left this month | for more free features.

Oligo-astrocytomas

Showing 1 - 25 of 156

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Astrocytoma, Oligo-Astrocytoma, Glioma Trial in Winston-Salem, Pittsburgh (GAA/TT-peptide vaccine and poly-ICLC)

Completed
  • Astrocytoma
  • +2 more
  • GAA/TT-peptide vaccine and poly-ICLC
  • Winston-Salem, North Carolina
  • +1 more
Aug 28, 2019

Oligodendroglioma, Astrocytoma, Grade II, Glioma, Astrocytic Trial in San Francisco (GBM6-AD and poly-ICLC before and after

Active, not recruiting
  • Oligodendroglioma
  • +5 more
  • GBM6-AD and poly-ICLC before and after surgery
  • GBM6-AD and poly-ICLC after surgery only
  • San Francisco, California
    University of California
Sep 20, 2022

Retrospective Cervical Cancer Oligo States Multicentre Outcomes

Not yet recruiting
  • Cancer, Cervical
  • +2 more
  • Concurrent Chemoradiation, Systemic Chemotherapy other locally directed therapies (like surgery, ablation, etc.)
  • (no location specified)
Nov 28, 2023

Astrocytoma Trial (Vorasidenib, Pembrolizumab)

Not yet recruiting
  • Astrocytoma
  • (no location specified)
Aug 1, 2022

Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Visual Pathway Glioma Trial in

Active, not recruiting
  • Neurofibromatosis Type 1
  • +2 more
  • Birmingham, Alabama
  • +125 more
Jan 25, 2023

Colorectal Cancer, Liver Metastasis Colon Cancer Trial in Edmonton (stereotactic body radiation treatment (SBRT))

Not yet recruiting
  • Colorectal Cancer
  • Liver Metastasis Colon Cancer
  • stereotactic body radiation treatment (SBRT)
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Mar 7, 2023

Metastatic Cancer Trial in Canada (Stereotactic Ablative Radiotherapy (SABR), Standard of Care Treatment)

Active, not recruiting
  • Metastatic Cancer
  • Stereotactic Ablative Radiotherapy (SABR)
  • Standard of Care Treatment
  • Edmonton, Alberta, Canada
  • +6 more
Aug 22, 2022

Esophageal Cancer, Small Bowel Cancer, Gastroesophageal-junction Cancer Trial in Sacramento (Ablative local therapy)

Recruiting
  • Esophageal Cancer
  • +10 more
  • Ablative local therapy
  • Sacramento, California
    University of California, Davis
Oct 27, 2023

NSCLC, Oligoprogressive, Small-cell Lung Cancer Trial in Sacramento (Ablative local therapy)

Recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Ablative local therapy
  • Sacramento, California
    University of California, Davis
Oct 27, 2023

Brain Metastases, NSCLC Trial in Shanghai (EGFR-TK Inhibitor, Stereotactic radiotherapy)

Recruiting
  • Brain Metastases
  • Non-small Cell Lung Cancer
  • EGFR-TK Inhibitor
  • Stereotactic radiotherapy
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 27, 2023

Breast Cancer, Oligoprogressive, Head Neck Cancer Trial in Sacramento (Ablative local therapy)

Recruiting
  • Breast Cancer
  • +4 more
  • Ablative local therapy
  • Sacramento, California
    University of California, Davis
Oct 19, 2023

Prostate Cancer, Oligoprogressive, Urothelial Carcinoma Trial in Sacramento (Ablative local therapy)

Recruiting
  • Prostate Cancer
  • +3 more
  • Ablative local therapy
  • Sacramento, California
    University of California, Davis
Oct 19, 2023

Prediction of True Oligo-metastatic Disease.

Recruiting
  • Oligometastatic Disease
  • Genetic and immunologic assessments
  • Naples, Italy
    Alessandro Ottaiano
Apr 7, 2023

HER2-positive Breast Cancer Trial in Amsterdam (Trastuzumab deruxtecan)

Not yet recruiting
  • HER2-positive Breast Cancer
  • Trastuzumab deruxtecan
  • Amsterdam, Netherlands
    Antoni van Leeuwenhoek
Aug 7, 2023

NSCLC, Stage IV, Oligometastasis Trial in Netherlands, Spain, Switzerland (drug, radiation, procedure)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Milano, Italy
  • +12 more
Dec 14, 2022

Irritable Bowel Syndrome, Obesity, Abdominal Obesity Trial (procedure, behavioral, other)

Not yet recruiting
  • Irritable Bowel Syndrome
  • +2 more
  • focused ultrasound
  • +2 more
  • (no location specified)
May 30, 2023

Radiation Toxicity Trial in Taipei (fucoidan)

Recruiting
  • Radiation Toxicity
  • fucoidan
  • Taipei, Please Select, Taiwan
    Szu-Yuan Wu
Nov 13, 2022

Juvenile Pilocytic Astrocytomas, Optic Pathway Gliomas Trial in Atlanta (Pegylated interferon alpha-2b)

Completed
  • Juvenile Pilocytic Astrocytomas
  • Optic Pathway Gliomas
  • Pegylated interferon alpha-2b
  • Atlanta, Georgia
    Children's Healthcare of Atlanta
Jan 18, 2022

Oligoprogressive Renal Cell Carcinoma Trial in Dallas (Stereotactic ablative body radiation (SABR))

Active, not recruiting
  • Oligoprogressive Renal Cell Carcinoma
  • Stereotactic ablative body radiation (SABR)
  • Dallas, Texas
    University of Texas Southwestern Medical Center
Nov 28, 2022

Glioblastoma, Glioma Trial in Denmark, Netherlands, United States (Selinexor)

Terminated
  • Glioblastoma
  • Glioma
  • Boston, Massachusetts
  • +5 more
Jan 24, 2023

Oligometastatic Disease, NSCLC, Driver Mutation Trial in Mumbai (Local Consolidative Radiation Therapy, TKI)

Recruiting
  • Oligometastatic Disease
  • +2 more
  • Local Consolidative Radiation Therapy
  • TKI
  • Mumbai, Maharashtra, India
    Tata Memorial Hospital
Mar 11, 2022

Breast Cancer Trial in Amsterdam (carboplatin, thiotepa, and cyclophosphamide, chemo (docetaxel, doxorubicin, cyclofosfamide,

Recruiting
  • Breast Cancer
  • carboplatin, thiotepa, and cyclophosphamide
  • chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)
  • Amsterdam, Netherlands
    NKI-AVL
Mar 21, 2022

3T MRI of Intramedullary Spinal Cord Tumours

Recruiting
  • Spinal Cord Tumor of Cervical Spine
  • MRI scan
  • Oxford, Oxfordshire, United Kingdom
    John Radcliffe Hospital
Dec 15, 2022

Prostate Cancer Trial in Netherlands (Radiotherapy, Leuprorelin)

Recruiting
  • Prostate Cancer
  • Leeuwarden, Friesland, Netherlands
  • +12 more
Apr 5, 2022

ULTRASONOGRAPHIC EVALUATION OF OVARIAN STROMA IN PCOS WOMEN

Completed
  • Ovarian Cysts
    • Usak, Turkey
      İrem Şenyuva
    Sep 18, 2022